Renovaro Biosciences Price To Book vs. Cash Flow From Operations
| RENB Stock | 0.69 0.08 12.95% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.19 | 0.21 |
|
|
For Renovaro Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Renovaro Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Renovaro Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Renovaro Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Renovaro Biosciences over time as well as its relative position and ranking within its peers.
Renovaro |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Renovaro Biosciences Cash Flow From Operations vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Renovaro Biosciences's current stock value. Our valuation model uses many indicators to compare Renovaro Biosciences value to that of its competitors to determine the firm's financial worth. Renovaro Biosciences is currently regarded as top stock in price to book category among its peers. It also is currently regarded as top stock in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Renovaro Biosciences' earnings, one of the primary drivers of an investment's value.Renovaro Cash Flow From Operations vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Renovaro Biosciences |
| = | 0.99 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Renovaro Biosciences |
| = | (10.97 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Renovaro Cash Flow From Operations Comparison
Renovaro Biosciences is currently under evaluation in cash flow from operations category among its peers.
Renovaro Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Renovaro Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Renovaro Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Renovaro Biosciences' change in net profit over the period of time. It can combine multiple indicators of Renovaro Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -170.8 K | -162.3 K | |
| Operating Income | -81.6 M | -77.6 M | |
| Income Before Tax | -80.7 M | -76.6 M | |
| Net Loss | -80.7 M | -76.6 M | |
| Total Other Income Expense Net | 989.1 K | 1 M | |
| Interest Income | 103.6 K | 72.3 K | |
| Net Loss | -35.7 M | -37.5 M | |
| Non Operating Income Net Other | 550.5 K | 578 K | |
| Net Loss | -35.7 M | -37.5 M | |
| Income Tax Expense | 1.00 | 1.05 | |
| Net Interest Income | -636.3 K | -604.5 K | |
| Change To Netincome | 26.6 M | 16.6 M | |
| Net Loss | (0.84) | (0.88) | |
| Income Quality | 0.14 | 0.13 | |
| Net Income Per E B T | 0.90 | 0.77 |
Renovaro Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Renovaro Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Renovaro Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Renovaro Biosciences' important profitability drivers and their relationship over time.
Use Renovaro Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Renovaro Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Renovaro Biosciences will appreciate offsetting losses from the drop in the long position's value.Renovaro Biosciences Pair Trading
Renovaro Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Renovaro Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Renovaro Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Renovaro Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Renovaro Biosciences to buy it.
The correlation of Renovaro Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Renovaro Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Renovaro Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Renovaro Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Renovaro Biosciences position
In addition to having Renovaro Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Fabricated Products Thematic Idea Now
Fabricated Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Fabricated Products theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Fabricated Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project Renovaro Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Renovaro Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Renovaro Biosciences' income statement, its balance sheet, and the statement of cash flows.